Naltrexone Based MAT Programs
Naltrexone Based MAT Programs has no subcategories
|The structure of the services index and definitions of the terms contained herein were originally published in A Taxonomy of Human Services: A Conceptual Framework with Standardized Terminology and Definitions for the Field by the Information and Referral Federation of Los Angeles County, Inc., 3035 Tyler Ave., El Monte, CA 91731; Copyright (c) 1983, 1987, 1991. No part of this listing of human services terms and definitions may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electrical, mechanical, photocopying, recording or otherwise without the prior written permission of the Information and Referral Federation of Los Angeles County, Inc.|
This file's content displays in the left hand side margin of your Taxonomy - Directory of Services.
Above is the standard disclaimer required by AIRS INFOLINE, please consult locally or with AIRS as to what is appropriate to post for your system Taxonomy.
We do NOT recommend that you use MS Word to edit or manage this file, be sure to seek out a program or application that is a valid web authoring tool to do so.
You will want to be sure to retain the exact file name and extension when editing, saving, and re-uploading this file to your directory.
Medication assisted treatment (MAT) programs that use Naltrexone (Vivitrol) to help people with an opioid or alcohol use disorder abstain from or reduce their use of opioids or alcohol. The medication comes in a pill form or as an injectable. The pill form of naltrexone (ReVia, Depade) can be taken daily. The injectable extended-release form of the drug (Vivitrol) is administered intramuscular once a month. Naltrexone can be prescribed by any health care provider who is licensed to prescribe medications. To reduce the risk of precipitated withdrawal, patients are warned to abstain from illegal opioids and opioid medication for a minimum of 7-10 days before starting Naltrexone. If switching from methadone to naltrexone, the patient has to be completely withdrawn from the opioids. Naltrexone blocks the euphoric and sedative effects of drugs such as heroin, morphine, and codeine. It works differently in the body than buprenophine and methadone, which activate opioid receptors in the body that suppress cravings. Naltrexone binds and blocks opioid receptors, and is reported to reduce opioid cravings. There is no abuse or diversion potential with naltrexone. Naltrexone can also be used to treat alcohol use disorders. Oral Naltrexone and extended-release injectable Naltrexone can be used for the treatment of alcohol dependence in patients who can abstain from alcohol in an outpatient setting before the initiation of treatment. Naltrexone has not been shown to be effective in patients who are drinking at treatment initiation. Both formulations may have the greatest benefit in patients who can discontinue drinking on their own for several days before treatment initiation.
Navigation Tips [+/-]